(2Z, 4E)-5-(5, 6-dichloro-2-indolyl)-2-methoxy-N-(1, 2, 2, 6, 6-pentamethylpiperidin-4-yl)-2, 4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V …
G Nadler, M Morvan, I Delimoge, P Belfiore… - Bioorganic & medicinal …, 1998 - Elsevier
G Nadler, M Morvan, I Delimoge, P Belfiore, A Zocchetti, I James, D Zembryki…
Bioorganic & medicinal chemistry letters, 1998•ElsevierOptimisation of a novel series of osteoclast ATPase inhibitors led to (2Z, 4E)-5-(5, 6-dichloro-
2-indolyl)-2-methoxy-N-(1, 2, 2, 6, 6-pentamethylpiperidin-4-yl)-2, 4-pentadienamide (1) that
was the most potent compound in an in vitro osteoclast ATPase assay and in human bone
resorption assays. Two of the possible geometric isomers have also been prepared and
shown to be significantly less potent than 1.
2-indolyl)-2-methoxy-N-(1, 2, 2, 6, 6-pentamethylpiperidin-4-yl)-2, 4-pentadienamide (1) that
was the most potent compound in an in vitro osteoclast ATPase assay and in human bone
resorption assays. Two of the possible geometric isomers have also been prepared and
shown to be significantly less potent than 1.
Optimisation of a novel series of osteoclast ATPase inhibitors led to (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide (1) that was the most potent compound in an in vitro osteoclast ATPase assay and in human bone resorption assays. Two of the possible geometric isomers have also been prepared and shown to be significantly less potent than 1.
Elsevier